AVENIO ctDNA Analysis Kits V2 The complete NGS liquid biopsy solution

AVENIO ctDNA Analysis Kits Next-generation performance in liquid biopsies

Accelerating clinical research From liquid biopsy to next-generation sequencing (NGS), rapid advances are underway to expand the possibilities for new discoveries in oncology. Liquid biopsy, a novel approach to sample collection through a simple blood draw, offers exciting possibilities for use in cancer research. This minimally-invasive procedure provides easy sample access to a broad population, and enables the possibility for serial testing. Furthermore, circulating tumor DNA (ctDNA), obtained through liquid biopsy, may provide a more accurate representation of tumor heterogeneity since ctDNA...

The AVENIO ctDNA Analysis Kits V2: A portfolio of three NGS liquid biopsy assays Our portfolio of assays provide researchers the flexibility to select the panel that best meets their research needs, and enable labs to offer NGS liquid biopsy tests for various research applications from a single trusted source. The AVENIO ctDNA Analysis Kits V2 use intelligent panel design algorithms, molecular barcodes and error suppression methods1 that enable researchers to interrogate mutated regions in a variety of cancer applications. The technology applies population-scale data from public cancer databases...

Potential research applications The AVENIO ctDNA Analysis Kits V2 can support a variety of use cases. Here are two examples: Example A Targeted Kit Identify biomarkers in NCCN Guidelines3 Expanded Tumor Profiling Tumor Profiling First line Second line Surveillance Kit Monitor tumor burden longitudinally in lung cancer and colorectal cancer Identify biomarkers in NCCN Guidelines3 and emerging biomarkers relevant to clinical research Longitudinal Tumor Burden Monitoring Longitudinal Tumor Burden Monitoring Minimal residual disease Longitudinal Tumor Burden Monitoring Recurrence Expanded Tumor Profiling...

Streamlined, end-to-end workflow Go from sample extraction to reporting in five days Each step of the AVENIO ctDNA workflow has been optimized to deliver improved accuracy, efficiency and turnaround time.4 The workflow has been validated Library Generation Target Enrichment Analysis & Report AVENIO ctDNA Analysis Kits V2 on the Illumina® NextSeq™ 500/550/550Dx sequencer. AVENIO cfDNA Isolation Kit V2 AVENIO ctDNA Library Prep Kit V2 AVENIO ctDNA Enrichment Kit V2 AVENIO ctDNA Targeted, Expanded, and Surveillance Panels V2 AVENIO ctDNA Post-Hybridization Kit V2 With ctDNA Targeted, Expanded, or...

Robust, intuitive analysis and reports With a focus on clarity and simplicity, the AVENIO ctDNA Analysis Software helps minimize the complexity and effort required to generate extensive insights from oncology sequencing data. The system provides analytical details and reports on variant calling and sequencing quality metrics. Variant Calling Genes with identified variants Mutation class of detected variants (SNVs, Indels, Fusions, CNVs) Mutation frequency and number of mutant molecules detected Annotation from public databases Sequencing Quality Metrics Sequencing depth Coverage uniformity On-target...

With a growing portfolio of AVENIO next-generation sequencing products, Roche aims to make sequencing simple and accessible for everyday use. 1. N ewman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520. 2. N ewman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519. 3. National Comprehensive Cancer Network. http://www.nccn.org. Accessed...